XML 45 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (14,794) $ (10,848) $ (7,453)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 435 312 207
Capital loss 1 8   
Impairment of property and equipment    11 2
Stock-based compensation to employees, directors and non-employees consultants 4,907 3,325 1,819
Stock-based compensation to investor relations consultants 20 155 13
Decrease (increase) in other accounts receivable (166) 656 (307)
Decrease (increase) in prepaid expenses 269 (273) 59
Increase (decrease) in trade payables (424) 455 132
Increase in other accounts payable and accrued expenses 958 375 120
Increase in deferred revenues 4,284      
Increase in advance payment from United Therapeutics 1,576      
Decrease (increase) in interest receivable on short-term deposits (395) 15 (15)
Linkage differences and interest on short and long-term restricted lease deposit 35 (4) 1
Accretion of discount, amortization of premimum and changes in accrued interest from marketable securities 17      
Gain from sale of investments of available for sale marketable securities (3)      
Accrued severance pay, net 5 58 14
Net cash used in operating activities (3,275) (5,755) (5,408)
CASH FLOWS FROM INVESTING ACTIVITIES:      
Purchase of property and equipment (1,480) (962) (389)
Investment in short-term deposits (21,031)    (2,500)
Proceeds from short-term deposits    898 1,602
Proceeds from sale of property and equipment    29   
Investment in long-term deposits (1,125) (14) (12)
Repayment of long-term restricted deposit 6 13 3
Proceeds from sale and redemption of available for sale marketable securities 998      
Investment in available for sale marketable securities (8,165)      
Net cash used in investing activities (30,797) (36) (1,296)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Issuance of common stock and warrants, net of issuance costs    43,400 5,954
Exercise of warrants and options 632 3,661 2
Repayment of long-term loan    (24) (8)
Net cash provided by financing activities 632 47,037 5,948
Increase (decrease) in cash and cash equivalents (33,440) 41,246 (756)
Cash and cash equivalents at the beginning of the period 42,829 1,583 2,339
Cash and cash equivalents at the end of the period 9,389 42,829 1,583
Supplemental disclosure of cash flow activities:      
Taxes paid due to non-deductible expenses 14 11 7
Interest paid       2
Supplemental disclosure of non-cash activities:      
Purchase of property and equipment in credit 738 123 192
Issuance of shares in consideration of new facility construction 3,672      
Other receivables resulting from issuance of shares $ 13